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Abstract
Background: Mobile health (mHealth) technology has the potential to support the Chronic Care Model’s vision of closed
feedback loops and patient-clinician partnerships.
Objective: This study aims to evaluate the feasibility, acceptability, and short-term impact of an electronic health record–linked
mHealth platform (Orchestra) supporting patient and clinician collaboration through real-time, bidirectional data sharing.
Methods: We conducted a 6-month prospective, pre-post, proof-of-concept study of Orchestra among patients and parents in
the Cincinnati Children’s Hospital inflammatory bowel disease (IBD) and cystic fibrosis (CF) clinics. Participants and clinicians
used Orchestra during and between visits to complete and view patient-reported outcome (PRO) measures and previsit plans.
Surveys completed at baseline and at 3- and 6-month follow-up visits plus data from the platform were used to assess outcomes
including PRO completion rates, weekly platform use, disease self-efficacy, and impact on care. Analyses included descriptive
statistics; pre-post comparisons; Pearson correlations; and, if applicable, effect sizes.
Results: We enrolled 92 participants (CF: n=52 and IBD: n=40), and 73% (67/92) completed the study. Average PRO completion
was 61%, and average weekly platform use was 80%. Participants reported improvement in self-efficacy from baseline to 6
months (7.90 to 8.44; P=.006). At 6 months, most participants reported that the platform was useful (36/40, 90%) and had a
positive impact on their care, including improved visit quality (33/40, 83%), visit collaboration (35/40, 88%), and visit preparation
(31/40, 78%). PRO completion was positively associated with multiple indicators of care impact at 3 and 6 months.
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Conclusions: Use of an mHealth tool to support closed feedback loops through real-time data sharing and patient-clinician
collaboration is feasible and shows indications of acceptability and promise as a strategy for improving pediatric chronic illness
management.
(JMIR Mhealth Uhealth 2020;8(11):e11968) doi: 10.2196/11968
KEYWORDS
health services research; mHealth; eHealth; patient engagement; chronic illness; mobile phone

Introduction
Background
Optimal management of pediatric chronic illness requires a
different type of health care system [1,2]. Current models of
care organized around treating acute, episodic conditions no
longer meet the needs of the growing number of children with
chronic health problems [3,4]. Although, organizationally, care
is focused around the clinic visit, more than 99% of patients’
lives are spent outside of this context. The Chronic Care Model
positions informed, activated patients and prepared, proactive
clinicians as foundational to improved health outcomes.
However, it is difficult for most clinicians to be informed about
what happens outside of the clinic. In turn, most patients have
neither easy, understandable access to their own clinical data
nor systematic ways to reliably measure and communicate
changes in daily functioning. This is a missed opportunity for
optimizing health care. Failing to connect what happens
day-to-day with clinical decision-making leads to reactive
instead of proactive care based on hazy memories, missing
information, and subjective impressions of how things have
been going.
Mobile health (mHealth) technology offers the opportunity to
address these gaps by expanding care beyond the boundaries
of time-limited, infrequent clinical encounters to support data
sharing, communication, and collaborative decision-making
between patients and clinicians [5-9]. This potential has
encouraged considerable attention from the health care and
technology industries; however, we have yet to see mHealth
have a transformative effect on chronic care delivery systems
or outcomes. Although the number of digital health apps, portals,
and dashboards is rapidly increasing, evidence of their impact
has been mixed and modest [10]. Some studies have
demonstrated that mHealth supports improved engagement and
adherence. For example, text messaging interventions have
boosted attendance at pediatric HIV appointments [11] and have
increased adherence in pediatric asthma [12], type 1 diabetes
[13], and cardiac care [14]. Electronic health portals that track
patients’ symptoms and provide decision support have decreased
clinic visits and school absences in pediatric ulcerative colitis
[15] and decreased flares and missed parental work in pediatric
asthma [16]. Yet, there are countless other examples of mHealth
technologies that fail to improve self-management behaviors
or clinical outcomes [9,10,16-21]. In fact, a comprehensive
review of mHealth technology for chronic disease management
found that just over half impacted adherence behavior and only
39% impacted clinical outcomes [10]. In addition, studies show
that about half of the individuals that download health apps stop
using them, most soon after initial use [22,23].
https://mhealth.jmir.org/2020/11/e11968
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Both technological design elements and clinical care integration
likely contribute to an mHealth tool’s success or failure [24].
Tools that only enable tracking and display of user data may
build awareness but are likely insufficient to engage individuals
in health behavior change [24-26] and surmount the burden of
data entry [22]. Rather, mHealth tools that support the Chronic
Care Model’s vision of closed feedback loops and
patient-clinician partnership, through making data relevant,
understandable, and actionable and by facilitating collaboration,
are more likely to be adopted and retained [26,27]. Beyond the
technology itself, purposeful integration with clinical care, so
that both patients and clinicians understand the why and how
of incorporating mHealth tools, is paramount to achieving
impact [10,26,28].

Objectives
The purpose of this study is to test the feasibility, acceptability,
and short-term impact of using an mHealth tool to facilitate the
Chronic Care Model’s vision of closed feedback loops and
patient-clinician partnerships. As there was no available
commercial platform that reliably enabled the functionality
needed to support the Chronic Care Model’s approach to
continuous care, we developed an mHealth tool with patient
and clinician end users to support pediatric chronic care during
and between clinical encounters. The Orchestra platform [29]
was designed to enable proactive and collaborative chronic care
through (a) real-time sharing and visualization of clinical and
patient-generated (ie, patient-reported outcome, PRO) data, (b)
automated symptom surveillance with actionable alerts to signal
changes in patient status based on patient-generated data, and
(c) collaborative previsit planning. As a first step, this
prospective, preliminary pre-post study tested Orchestra in 2
pediatric chronic diseases (cystic fibrosis [CF] and inflammatory
bowel disease [IBD]). We hypothesized that parents, patients,
and clinicians would find Orchestra feasible and acceptable
and that we would see signals of clinically meaningful impact.

Methods
Setting and Patient Population
This study was conducted within the IBD and CF clinics at
Cincinnati Children’s Hospital (CCH; Ohio, United States) and
was approved by the CCH Institutional Review Board
(#2014-0975). We conducted the work at CCH because of our
existing relationships with clinics that had an interest and ability
to partner with us in this proof-of-concept study. We used a
convenience sample of patients and parents from the CCH CF
and IBD clinics. The CF and IBD clinics were chosen to ensure
that our study included conditions that varied in disease course,
management, and time demands associated with daily care.
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 11 | e11968 | p. 2
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Eligible participants were patients with IBD or CF aged between
14 and 21 years and/or a parent or legal guardian of patients
aged between 0 and 21 years. If a patient was less than 14 years
old, only their parent was enrolled in the study and used the
Orchestra app. If a patient was older than 14 years, the family
decided if only the patient, only the parent, or both would enroll
and use the Orchestra app. Participants were English speaking
or reading and had a smartphone (iOS or Android) with a mobile
data plan and/or internet connectivity.

Opipari-Arrigan et al
process. The platform included a patient- or parent-facing mobile
app and a linked clinician-facing web-based dashboard. Patient
or parent functionality included the following (Figure 1):
•

Study Design and Protocol
This was a preliminary, prospective pre-post, proof-of-concept
study. Recruitment began in May 2015 and continued for 1 year.
Follow-up data collection was completed in fall 2016. Eligible
participants were identified via clinic rosters and were contacted
by research staff, who were not part of the clinical team, before
or at a clinic visit. Interested participants watched a 3-min video
[30] describing Orchestra while waiting for their visit and then
discussed with their clinicians how they might use Orchestra
as part of their care. Following the visit, participants met with
staff to sign the informed consent form, download the Orchestra
mobile app, and customize settings. Participants were enrolled
for 6 months.

•
•
•

•

Orchestra Technology Platform

Library of PRO measures [31,32] that could be selected for
symptom and general health tracking based on patient goals
and customized for daily or weekly completion. There were
35 predetermined measures available for IBD (eg,
abdominal pain frequency, stool consistency, and fatigue)
and 28 available for CF (eg, energy level, cough severity,
and appetite). Participants could also create custom
symptoms with their clinician if needed (Multimedia
Appendix 1).
Real-time visualization of PRO data.
PRO data point annotation and journal entry features for
recording observations.
Previsit health report showing disease-specific laboratory
data (ie, C-reactive protein and hematocrit) and health
metrics (ie, weight and pulmonary function tests) with
simple visualizations and text descriptions of results and
trends as well as personalized suggestions for topics to
discuss with clinicians.
Previsit plan (PVP) completion to inform clinical teams
about patient symptoms, goals, and questions before a clinic
visit.

The Orchestra technology platform [29] was developed with
clinicians, patients, and parents via a user-centered, agile design
Figure 1. “Orchestra” participant mobile app example screens. PRO: patient-reported outcome; PVP: previsit plan.

The clinician-facing web-based dashboard was accessed via
Epic (Epic Systems Corporation), the electronic medical record,
using a customized configuration that enabled one-click, single
sign-on authentication. Clinical users included physicians and
nurses in IBD and physicians, nurses, dietitians, a social worker,
a respiratory therapist, and a psychologist in CF. The clinician
dashboard enabled the following (Figure 2):
•

Real-time visualization of PRO data and review of PVPs.

https://mhealth.jmir.org/2020/11/e11968
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•
•

Addition of notes to a patient’s account visible by the
patient or parent and other clinical staff.
Notification if a patient’s symptoms met prespecified
criteria based on PRO data. Alert triggers were customizable
and based on meeting a threshold value and/or meeting
standard statistical process control criteria of 8 data points
above or below the median after a 20-data point baseline
was established [33]. If alerts were triggered, clinicians
were notified via the Orchestra dashboard and email.
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Figure 2. “Orchestra” clinician dashboard example screens. PRO: patient-reported outcome; PVP: previsit plan.

Orchestra Intervention
Use of the Orchestra technology platform was accompanied by
a delivery system intervention to integrate the technology into
clinical workflows and patients’ lives, personalize goals for use,
and establish accountability for system use between participants
and clinicians. All clinicians who cared for patients, including
physicians, nurses, dietitians, a respiratory therapist, a social
worker, and a psychologist, received training on the use of
Orchestra [29]. Participants and clinicians used shared
decision-making during the baseline clinic visit to discuss their
preferences and goals for Orchestra use, select which PROs to
complete and at what frequency, and decide who (patient and/or
parent) would use the tool. Clinicians discussed health concerns
and goals with patients (eg, reducing symptoms, reducing
medications, and preventing exacerbations) and identified
whether using Orchestra would help achieve these goals. The
clinician and family then reviewed the PRO and symptom
measures available in Orchestra and determined which measures
were most relevant to addressing the identified goals. They also
established a social contract to set expectations regarding
between-visit data completion (by participant), review (by
clinician), and communication (participant-clinician). Clinicians
chose whether to set data alerts and customized trigger points
based on the PROs selected and patient needs.
To reinforce the use of Orchestra by demonstrating that data
collected between visits were reviewed, a designated clinical
team member was asked to review the data entered into the
Orchestra platform each week and within 1 day of receiving a
data alert. In addition, clinicians were asked to review PVP and
PRO data before all clinic visits. At visits, clinicians were
encouraged, at least, to verbally acknowledge reviewing the
data and ideally to use the data for discussion and decision
making.

Data Collection
Participants completed study assessments at baseline and 3- and
6-month follow-up visits during regularly scheduled clinic
appointments. As this tool was designed to be used as part of
clinical care, if a patient did not have a clinic appointment within
https://mhealth.jmir.org/2020/11/e11968
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±1 month of a follow-up time point, the assessment was not
completed. Participants were still included in the study if they
did not have an appropriately timed follow-up visit, but that
specific assessment was considered missing.
Health status indicators, including the Physician Global
Assessment (PGA) Score (IBD) and forced expiratory volume
in 1 second (FEV1) percent predicted (CF), were collected from
the electronic health record to understand the baseline health
of participants. The PGA score is an indicator of disease severity
that is rated at each clinic visit by the physician and is based on
symptoms, clinical exam, and laboratory measures [34]. PGA
is used to classify disease as in remission, mild, moderate, or
severe. FEV1 is calculated as part of pulmonary function testing
and is an established marker of disease progression in CF [35].
The lower the FEV1 percent predicted, the more severe the lung
disease.
Clinicians and research staff reported on baseline technology
discussion and set-up time via a paper and pencil measure
completed immediately following the patient visit. In addition,
the patient’s physician and, if applicable, a second clinical team
member involved in using Orchestra completed surveys after
each visit regarding their assessment of the patient and parent’s
engagement in the visit and their experience using Orchestra.
However, due to an inability to obtain responses in a timely
manner from clinicians, the data were not analyzed.

Outcomes
The feasibility of implementing and supporting Orchestra in
care was assessed by measuring the percentage of eligible
patients with access to a smartphone with data plan or internet
connectivity, minutes spent discussing Orchestra (self-reported
by the clinician at baseline), minutes spent enrolling and setting
up the Orchestra app (self-reported by research staff), and
participants’ report of whether Orchestra was used during
follow-up visits. One facet of acceptability was assessed by
measuring usage of the app including PRO completion (ie,
percentage of PROs a participant answered), weekly engagement
with the mobile app (ie, percentage of weeks a participant input
data at least once), and PVP completion (percentage of PVPs
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 11 | e11968 | p. 4
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that were submitted in the app). We examined the short-term
impact of Orchestra on disease self-efficacy, visit engagement,
and care impact, including perceived care quality,
patient-clinician collaboration, visit preparation, disease insight,
treatment plan quality, and perceived usefulness. As we did not
expect health outcomes to change over the 6-month study period,
we focused on measures of short-term meaningful clinical
impact that reflected participants’ perceptions of their ability
to manage their illness (efficacy) as well as their perceptions of
their clinic visit and interaction with their clinicians. Disease
self-efficacy was measured using the validated Self-Efficacy
for Managing Chronic Disease 6-Item Questionnaire [36,37].
Each item uses a 1 (not at all confident) to 10 (totally confident)
scale, and a mean of all items is calculated. Visit engagement
was measured using an 8-item survey examining visit
preparation, knowledge, and involvement given at baseline and
at the 3- and 6-month follow-up (Multimedia Appendix 2). As
one item assessed the use of tracked data at clinic visits, it was
assessed only at 3 and 6 months and was not included in the
analysis. At 3 and 6 months only, participants completed a
20-item care impact survey that measured the impact of
Orchestra on care quality (4 items), patient-clinician
collaboration (2 items), visit preparation (6 items), disease
insight (3 items), treatment plan quality (3 items), and perceived
usefulness (2 items; Multimedia Appendix 2). Both the visit
engagement and care impact surveys were developed
theoretically by a team of experts for this study, used a 6-point
scale ranging from 1 (strongly disagree) to 6 (strongly agree),
and were tested in a convenience sample for understandability.
The 3- and 6-month surveys also included a single question
measuring overall satisfaction: “How likely are you to
recommend Orchestra to other parents/patients like you?”, which
respondents answered on a 10-point scale from 10 (very likely)
to 1 (not at all likely). Impact on the treatment plan was
measured by chart review examining the percentage of data
alerts that led to documented clinical action including phone
calls, emails, or messages to check status; expedited clinic
appointments or laboratory tests; referrals; or treatment changes.

Statistical Analyses
Descriptive statistics, including means and ranges for continuous
variables and percentages for categorical variables, were used
to describe the study population, feasibility, acceptability,
satisfaction, and perceived impact. A mean score of 4 or higher
on the visit engagement survey and care impact survey subscales
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was defined as an indicator of engagement in the visit and
improvement in care experience, respectively. t tests were used
to assess the impact of condition (CF or IBD), person using
Orchestra (parent or patient), and baseline health status in CF
(FEV1: ≥70% predicted or <70% predicted) on PRO completion.
Cohen d measured the effect size. Univariate analysis of
variance tests was used to evaluate differences in acceptability
measures across study clinicians and across IBD baseline health
status (PGA: continuous remission, remission, mild, and
moderate). Paired t tests examined the impact on disease
self-efficacy and visit engagement from baseline to 6-month
follow-up. Pearson correlation coefficients examined the
relationships between PRO completion and perceived impact
on care. Analyses were conducted using the Statistical Package
for the Social Sciences v23 (SPSS, IBM Corp).
We aimed to enroll 100 participants. Our target was based on
knowledge of the eligible population in each clinic, frequency
of clinic visits, available research resources, and a desire to
complete the study while the technology remained current. As
efficacy was not the primary endpoint, we did not perform an
a priori power calculation.

Results
Overview
Of the 127 families approached, 88 (69.2%) agreed to
participate. A total of 92 participants (CF: n=52 and IBD: n=40)
from 88 families enrolled in the study (Figure 3). In 38 families
(38/88, 43%), an adolescent patient participated; in 46 families
(46/88, 52%), a parent participated; and in 4 families (4/88;
5%), both participated. At 3 months, 71 of the original 92
participants (77%) remained in the study; at 6 months, 67 of
the original 92 participants (73%) remained (Figure 3). The
6-month retention rate was higher among IBD clinic participants
(32/40, 80%) than among CF clinic participants (35/52, 67%).
Eight different attending physicians had participants enrolled
on the platform, 2 from IBD and 6 from CF. This included all
attending physicians in the CF clinic and the physicians who
most frequently saw patients with IBD in the gastroenterology
clinic. Table 1 describes the demographic and health status
characteristics of the participants. Characteristics of the
participants mirrored the general demographics of the clinic
populations. Participants selected an average of 4.96 PROs
(range: 1-13) to track in the app.
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Figure 3. Participant flow diagram. Of the 127 eligible families, 88 were enrolled (92 participants). At 3 months, 77% (71/92) of participants remained
in the study and 66% (47/71) completed the 3-month follow-up within the specified study time window. At 6 months, 74% (67/92) of the participants
remained in the study and 63% (42/67) completed the 6-month follow-up within the specified study time window.
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Table 1. Baseline demographic and health status characteristics of the patients for each enrolled family.
Patient characteristics

Cystic fibrosis (n=51) Inflammatory bowel disease (n=37)

Full sample (N=88)

Patient age (years), mean (SD)

10.55 (6.01)

15.70 (4.02)

12.72 (5.82)

0-2, n (%)

7 (14)

1 (3)

8 (9)

3-12, n (%)

24 (47)

9 (24)

33 (38)

12-21, n (%)

20 (39)

27 (73)

47 (53)

Female

24 (47)

22 (60)

46 (52)

Male

27 (53)

15 (40)

42 (48)

White

49 (96)

35 (95)

84 (96)

Black or African American

0 (0)

2 (5)

2 (2)

Other

2 (4)

0 (0)

2 (2)

—c

—c

Patient gender, n (%)

Patient race, n (%)

Disease indicators, mean (SD)
Mean forced expiratory volume in 1 second percent predict- 96.89 (19.69)
eda,b (cystic fibrosis only, n=38)
Disease type (inflammatory bowel disease only)

—d

•
•

Crohn: 29 (78%)
Ulcerative Colitis: 8 (22%)

—d

Physicians global assessment score (inflammatory bowel
disease only)

—d

•

Continuous Remission: 10
(27%)
Remission: 14 (38%)
Mild: 11 (30%)
Moderate: 2 (5%)

—d

•
•
•
Family income (US $), n (%)

a

<25,000

4 (8)

3 (8)

7 (8)

25,000 to 49,999

12 (24)

1 (2)

13 (15)

50,000 to 74,999

8 (15)

5 (14)

13 (15)

75,000 to 99,999

9 (18)

7 (19)

16 (18)

≥100,000

15 (29)

14 (38)

29 (33)

Unknown

3 (6)

7 (19)

10 (11)

Scores ranged between 48 and 127.

b

Not all participants were old enough to reliably complete pulmonary function testing.

c

Measure not applicable for patients with inflammatory bowel disease.

d

Measure not applicable for patients with cystic fibrosis.

Feasibility
Access to technology was not a significant barrier to
participation. Of the families approached, 119 of 127 (94%)
had regular access to an eligible device and internet connectivity.
Most participant-clinician conversations about Orchestra (40/83,
48%) required 5-10 min, with 34% (28/83) taking <5 min and
18% (15/83) requiring >10 min. Orchestra enrollment and app
installation took 14 min on average (SD 7; 95% CI 13-16),
ranging between 2 and 43 min (data available for n=84 families).
Longer set-up times were related to technical issues or need for
more thorough instruction. It was feasible to incorporate
Orchestra into follow-up clinic visits—participants reported
discussing Orchestra in 83% (34/41) of visits at 3 months and
in 71% (29/41) of visits at 6 months.
https://mhealth.jmir.org/2020/11/e11968
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Acceptability
Among those who used the PRO feature (n=80), 19,954 PROs
were completed. The average PRO completion rate by
participants was 61% (range: 6%-100%; 95% CI 55-68). There
was no difference in mean PRO completion rates between CF
(n=47, 58%; 95% CI 50-67) and IBD (n=33, 66%; 95% CI
58-75; P=.19). Parents (n=41) had significantly higher rates of
PRO completion (67%; 95% CI 59-76) than patients (n=39;
55%; 95% CI 46-64; P=04; Cohen d=0.46). Participant PRO
completion rates varied significantly across different physicians
(n=8), ranging between 38% and 77% (P=.02; partial eta
squared=0.20). PRO completion was not related to baseline
health status in CF (FEV1 percent predicted) or IBD (PGA
score), data not shown.
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Average weekly engagement, a measure of app stickiness that
indicates the participants’ willingness to return to the app, was
80% (n=80; range: 21%-100%; 95% CI 75-85). No significant
differences in weekly engagement were observed between CF
(n=47; 80%; 95% CI 73-87) and IBD (n=33; 80%; 95% CI
72-88; P=.99) or based on participants’ physicians (n=8; P=.06).
Parents (n=41) had a higher rate of weekly engagement (87%;
95% CI 81-92) compared with patients (n=39; 73%; 95% CI
65-81; P=.005; Cohen d=0.64). Patients with IBD in continuous
remission for ≥1 year based on PGA (n=6) showed lower weekly
engagement (55%; 95% CI 28-83) than patients in current
remission for <1 year (n=13; 84%; 95% CI 71-96) or those rated
as having mild (n=12; 86%; 95% CI 75-98]) or moderate (n=2;
93%; 95% CI 2-184) disease activity (P=.02; partial eta
squared=0.28). No differences were found in the average weekly
engagement based on FEV1 status in CF (n=35).
Participants received three PVPs on average (range: 0-6) and
completed 49.4% (94/190). Most families who received a PVP
(56/76, 74%) completed the information at least once.

Short-Term Impact
Participants reported significant improvement in disease
self-efficacy from baseline (7.90, SD 1.63; 95% CI 7.70-8.34)
to the 6-month follow-up (n=40; 8.44, SD 1.34; 95% CI
8.01-8.87; P=.006; Cohen d=0.36). The majority of participants
reported feeling engaged in their clinic visit at baseline (87/92,
95%) and 6-month follow-up (38/40, 95%), and there was no
change in self-reported visit engagement scores from baseline
(5.13, SD 0.74; 95% CI 4.84-5.22) to 6-month follow-up (n=40;
5.29, SD 0.66; 95% CI 5.06-5.50; P=.12). Most participants
reported that incorporating Orchestra into care was useful and
had a positive impact on care quality, visit collaboration,
participant visit preparation, participant disease insight, and
treatment plan quality. Table 2 shows the percentage of
participants who responded that Orchestra improved their care
experience. Participants who used Orchestra more were more
likely to report greater perceived impact on care. As shown in
Table 3, the higher a participant’s PRO completion, the more
useful they found Orchestra and the more impact it had on
reports of care quality, visit collaboration, participant visit
preparation, and treatment plan quality at 3- and 6-month
follow-up visits.

Table 2. Percentage of Orchestra users reporting that the tool improved their care experience.

a

Impact on care experience

3-Month follow-up (n=44)a, n (%)

6-Month follow-up (n=40)b, n (%)

Improved care quality

40 (91)

33 (83)

Improved collaboration

37 (84)

35 (88)

Improved participant preparation for visit

35 (80)

31 (78)

Improved participant disease insight

33 (75)

29 (73)

Improved treatment plan

38 (86)

32 (80)

Perceived useful for visit

40 (91)

36 (90)

44 out of 47 participants completed the care impact survey at the 3-month follow-up.

b

40 out of 42 participants completed the care impact survey at the 6-month follow-up.

Table 3. Pearson correlation coefficients between patient-reported outcome completion rate and impact of Orchestra on care experience.
Impact on care experience

3-Month follow-up (n=43)a

P value

6-Month follow-up (n=39)b

P value

Improved care quality

0.52

<.001

0.33

.04

Improved collaboration

0.39

.009

0.38

.02

Improved participant preparation for visit

0.47

.002

0.34

.04

Improved participant disease insight

0.33

.03

0.07

.67

Improved treatment plan

0.51

<.001

0.36

.03

Perceived useful for visit

0.51

<.001

0.22

.18

a

44 out of 47 participants completed the care impact survey at the 3-month follow-up, and 43 out 47 participants received regular patient-reported
outcomes (n=1, used tool for previsit plan only).
b

40 out of 42 participants completed the care impact survey at the 6-month follow-up, and 39 out of 42 participants received regular patient-reported
outcomes (n=1, used tool for previsit plan only).

Participants reported moderately high satisfaction (ie, likelihood
of recommending to others) with using Orchestra at the 3-month
(mean 8.16, SD 1.76; n=45) and 6-month follow-ups (mean
8.55, SD 2.05; n=40).
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Clinicians set optional alerts for 49 of 92 (53%) participants. A
total of 192 alerts were triggered among 35 of the 49 (71%)
patients. On the basis of the clinician report and medical record
review, 39% (74/192) of alerts led to documented, actionable
clinician behavior. For example, in one case, the CF team was
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signaled about a change in mucous production and cough based
on Orchestra alerts. This prompted a phone call to the family
who had noted the symptoms but had not acted on them. The
clinical team was able to initiate early treatment (antibiotics
and increased airway clearance) and potentially avoid an
inpatient admission for pulmonary exacerbation. More than half
(65/111, 59%) of alerts in IBD led to action as compared with
only 11% (9/81) in CF.

Discussion
Principal Findings
We tested a technology platform and care delivery system
intervention designed to support the Chronic Care Model’s
vision of informed patients and prepared clinicians working in
partnership with closed feedback loops. This proof-of-concept
study suggests that the mHealth platform is feasible, acceptable,
and shows promise for clinically meaningful impact. The
average PRO completion rate by participants across the 6 months
of the study was 61%, and the average weekly platform use was
80%, suggesting reasonable acceptability. Participants reported
significant improvement in self-efficacy from baseline to 6
months. At 6 months, most participants reported that the
platform was useful and had a positive impact on their care,
including improved visit quality, visit collaboration, and visit
preparation. PRO completion rate was moderately associated
with participant-reported visit preparation, care quality,
treatment plan quality, collaboration, disease insight, and
usefulness at 3 months. All relationships, except disease insight
and usefulness, remained significant, although weaker, at 6
months.
The addition of shared mHealth technology into the process of
managing chronic disease enabled frequent, timely, and
problem-focused information and communication. We posit
that these types of real-time, bidirectional shared data potentiate
a fundamental shift in the interaction between clinician and
patient—a shift from clinician as the expert delivering care to
a relatively passive patient, to clinician and patient contributing
to shared work in which the expertise of both is needed. Our
findings are consistent with the small number of mHealth studies
specifically designed to facilitate patient-clinician collaboration
that also show early evidence of effectiveness [16,38] and, as
hypothesized, demonstrate that collaboration is associated with
sustained use [26]. For example, a pilot study compared pediatric
patients with asthma receiving standard care versus access to a
portal that included symptom tracking, sharing of concerns and
goals, and symptom threshold–based prompts [16]. In this study,
more than half of the parents completed >80% of monthly
surveys, and they reported improved communication, fewer
asthma flares, and less missed work compared with standard
care. Orchestra achieved similar rates of engagement (80%
average weekly engagement) and sustained use (almost 60% of
participants engaged for ≥24 weeks). Our work extends these
results by demonstrating high rates of use in two other chronic
pediatric diseases. We were also able to show that incorporating
processes to support patient-clinician collaboration and closed
feedback loops, including shared decision-making to establish
goals for technology use and reinforcement of PRO completion
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through regular review and use of the data, is feasible to
implement in a busy clinical setting. The benefits of focusing
on mHealth users’ goals and their commitment to these goals
were also underscored in a longitudinal study of mHealth app
usage. This study showed that the key to successful use of
mHealth technology revolved around persisting at goals while
using the right system that fits users’ needs [23].
A key strength of our approach was that we focused not only
on user-centered technology but also on the processes to support
integration into workflow, closed feedback loops, and
patient-clinician collaboration. This attention to helping our end
users (ie, patients and clinicians) understand the value of
between-visit data and feel comfortable with using it was critical
to the tool’s acceptability and sustained use. Although mHealth
apps alone often function as sophisticated data collection and
delivery mechanisms, when well-integrated into care, they may
support patients and clinicians in moving beyond traditional
role expectations to learning to work together in new ways that
transform their interactions, health care, and outcomes [39,40].
Given that participants were delivered PROs to complete once
per day, the greater than 60% PRO completion rate seen in this
study means that participants recorded health data on average
about 4 days per week between clinic visits, resulting in a
significant amount (almost 20,000 completed PROs) of
previously untapped information that was available to inform
care. Although technology enables easy data collection, more
data are not always better, and it can easily overwhelm clinical
teams [9]. Giving clinicians the ability to set data alerts was
done as a way to help manage the volume of data in busy clinical
workflows by highlighting potentially actionable information.
Incorporating statistical process control methods to assist with
identifying meaningful changes from the patient’s unique
baseline was a novel approach. Although alerts were only set
for about half of the patients, almost 40% of the alerts that fired
led to documented action between clinic visits. Interestingly,
more alerts were acted upon in IBD versus CF. Several factors
may explain this finding, including more experience among our
IBD physicians in selecting and using daily PROs; the complex,
multisystem nature of CF; and the sensitivity of the alert
threshold chosen by the physicians. Additional work is needed
to understand how to balance sensitivity to detect meaningful
changes in patient status with the volume of alerts generated.
We speculate that the right balance will differ by condition and
by patient.
Our data suggested that participants who used Orchestra more
reported greater perceived impact on care. We found that the
higher a participant’s PRO completion rate, the more they
reported that Orchestra had a positive impact on care quality,
visit collaboration, participant visit preparation, and treatment
plan quality. We hypothesize that PROs, PVP data, real-time
visualizations, and alerts better enabled patients and clinicians
to work together between and during visits, leading to
improvements in short-term outcomes. Specifically, we posit
that by responding to daily or weekly PROs, participants had a
systematic way to learn, remember, and communicate with
clinicians between visits. In turn, the data potentiated clinicians
being more informed during clinical contacts and better able to
proactively address problems between visits. Another reason
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participants who completed more PROs may have reported
greater benefits relates to the potential for closed feedback loops
that reinforce platform use. Use of shared decision-making at
the onset may have increased the likelihood that the data
collected had relevance to both the clinician’s and participant’s
goals, creating greater potential for relevant, actionable data.
In turn, the potential for relevant, actionable data could have
increased the probability that participants entered it and that
clinicians reviewed it and talked about it at visits (reported in
83% of visits at 3 months and in 71% of visits at 6 months). As
clinicians used tracked data, we believe that participants’ efforts
were reinforced, leading to sustained data collection and more
actionable results. A stronger relationship between tool use and
care impact was found at 3 months as compared with 6 months.
We hypothesize that this may be related to the length of the
intervening time between the goal for tool use being discussed
and PROs selected and the subsequent clinic visit. Patients and
clinicians determined how and why the tool would be used at
baseline only. It may be that 6 months later, the data are less
valuable due to essential learning already occurring (perhaps at
a prior visit) and/or areas of concern changing. More frequent
recalibration between patients and clinicians (ie, every visit)
may be needed to sustain the relevance of mHealth tool use in
chronic care.
Our findings reveal several factors that may contribute to
improved engagement with mHealth technology. Involvement
of the clinical team in supporting participants’ platform use is
critical [26]. Differences in PRO completion rates across
physicians and a tendency for participants’ weekly engagement
to vary by physician is consistent with observations that
clinicians varied in skill at helping patients identify goals for
tool use and integrating Orchestra data into follow-up visits.
Understanding how to help clinicians maximize patients’
engagement and use of mHealth technology will be important
for future interventions. Not surprisingly, parents showed higher
levels of overall PRO completion and weekly app engagement
as compared with teens. However, teens completed over half
of the PROs they were sent. With realistic expectations for app
use, this type of mHealth technology could support adolescent
care transition. The finding that health status predicted weekly
engagement in IBD but not CF suggests that disease course may
lead to different patterns of app use. In IBD, participants in
continuous remission used the app less than those who were
not. Frequent PRO completion during periods of sustained
wellness is likely a low-value behavior. In CF, a condition with
periods of exacerbation but no remission, app use was not related
to health status, suggesting that PRO completion behavior may
be influenced by the interplay of disease course and current
functioning. Although these two conditions differ significantly
in required time for daily self-management, with CF typically
being more intensive, average app use across the diseases did
not differ, suggesting feasibility even in the context of high
disease self-management demands.

Limitations
This study had some limitations. Our evaluation of app use and
impact is based on participants’ perspectives only. We attempted
to collect clinician data on tool use and impact following clinical
encounters but were unsuccessful in getting clinicians to
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complete surveys in a timely manner. Rather than asking
physicians to complete the surveys immediately after the visit,
we allowed them to answer them later by email. In future work,
we will gather the data as soon as the physician leaves the clinic
room or consider obtaining clinicians’ perspectives via
qualitative interviews. As this study focused on proof of concept,
we did not include a contemporaneous control group, so it is
unclear how those receiving standard care felt about their visits
and ability to communicate with their providers in between
visits or whether self-efficacy would have gradually improved
over time even without the use of Orchestra. It is not possible
to rule out that either natural history led to the clinical impact
observed or that selection bias led to those who were most
interested in technology and collaboration choosing to
participate, stay in the study, and show benefit. By using limited
exclusion criteria, a pragmatic approach that utilized existing
clinic visits (rather than research study visits), and studying
more than one chronic disease, we attempted to lessen the impact
on these potential threats to validity. Although our participants
spanned the economic spectrum, one-third of the families
included in this study had incomes above US $100,000.
Although convenience sampling made sense in this early work,
in future studies, using sampling techniques to ensure
appropriate representation across the economic spectrum is
critical. It will also be important to ensure that this type of
technology and intervention does not increase health disparities.
Some measures were developed for this study because of the
lack of validated instruments to evaluate visit engagement and
the impact of the mHealth tool on care. These measures had
face validity and were tested for understandability, but we did
not conduct psychometric testing to examine factor structure,
reliability, or validity. As this was designed as a pragmatic
study, we only attempted to collect follow-up data from
participants if they had a clinical visit during the follow-up
window. As a result, we do not have the follow-up questionnaire
data on the full sample at either time point. For example, at 6
months, approximately two-third of the participants (42 of 67)
who remained in the study had a clinic visit. There could have
been systematic differences between participants who returned
to the clinic more and less often. However, given that the intent
of the study was as a proof of concept, identifying a tool that
may have had a meaningful impact for even a fraction of the
patients who used it is beneficial learning.

Lessons Learned
The lessons learned in this process are important for future work
on mHealth tools for chronic illness. First, the value of working
iteratively and in concert with patient and clinician end users
cannot be overstated. Through collaborative development, they
showed us their pain points and thus the necessary functionality
to sustain engagement. Second, the one-click, single sign-on
with the electronic medical record was critical for our clinicians
to sustain use. Although for a short time they were excited by
the novelty of a new platform, its use was not sustainable in
their workflow if it was not reachable from the electronic
medical record. Third, the automated data signals were critical
in facilitating clinician comfort with between-visit data
collection and thus having multiple patients on the platform.
Fourth, both clinicians and patients needed time to learn the
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value of between-visit data. Structuring workflow to encourage
using the data facilitated the learning and was key. Finally,
reliable and low-friction technology is necessary, but not
sufficient, to support engagement over time. Rather,
understanding patients’ and clinicians’ needs and goals and then
using technology to support achieving them is essential for
impacting health care and outcomes.

Conclusions
We have shown that the use of an mHealth technology designed
to facilitate the Chronic Care Model’s vision of closed feedback

Opipari-Arrigan et al
loops and patient-clinician partnerships is feasible, acceptable,
and shows promise as a strategy for improving pediatric chronic
illness management. These encouraging early results reinforce
the potential of mHealth technology to support collaboration
and real-time data sharing. Although the start-up company that
developed Orchestra is no longer supporting the platform, this
proof-of-concept study identifies key components necessary in
any mHealth platform designed to support continuous data and
patient-clinician collaboration, important processes necessary
to include in clinician and patient workflows to facilitate
technology use, and lessons for future studies.
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